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Structural basis for extracellular cis and trans
RPTPs signal competition in synaptogenesis
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Receptor protein tyrosine phosphatase sigma (RPTPs) regulates neuronal extension
and acts as a presynaptic nexus for multiple protein and proteoglycan interactions during
synaptogenesis. Unknown mechanisms govern the shift in RPTPs function, from outgrowth
promotion to synaptic organization. Here, we report crystallographic, electron microscopic
and small-angle X-ray scattering analyses, which reveal sufﬁcient inter-domain ﬂexibility in
the RPTPs extracellular region for interaction with both cis (same cell) and trans (opposite
cell) ligands. Crystal structures of RPTPs bound to its postsynaptic ligand TrkC detail an
interaction surface partially overlapping the glycosaminoglycan-binding site. Accordingly,
heparan sulphate and heparin oligomers compete with TrkC for RPTPs binding in vitro and
disrupt TrkC-dependent synaptic differentiation in neuronal co-culture assays. We propose
that transient RPTPs ectodomain emergence from the presynaptic proteoglycan layer allows
capture by TrkC to form a trans-synaptic complex, the consequent reduction in RPTPs
ﬂexibility potentiating interactions with additional ligands to orchestrate excitatory synapse
formation.
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N
euronal synaptogenesis is orchestrated by cell surface
receptors, which deﬁne the formation and functionality of
distinct synapse classes1,2. These ‘organizer’ molecules
can act as scaffolds or hubs, to integrate multiple inputs into a
uniﬁed cellular response. This concept is well established for
intracellular systems, but only now emerging for cell surface
molecules such as neurexin-neuroligin and repulsive guidance
molecule (RGM)-neogenin protein complexes3–5. At the axonal
surface, type IIa receptor protein tyrosine phosphatases (RPTPs)
(type IIa RPTPs, for example, RPTPs, RPTPd and leukocyte
common antigen-related (LAR) in vertebrates, dLAR in
Drosophila), are a recently identiﬁed nexus for extracellular inter-
actions, receiving signals and transmitting them intracellularly to
the cytoskeleton to regulate neuronal extension and guidance, as
well as synaptic organization6–9.
Heparan sulphate proteoglycans (HSPGs) and chondroitin
sulphate proteoglycans (CSPGs) play important roles in the
modulation of RPTP signalling in the nervous system10–15. At the
Drosophila neuromuscular junction, the HSPGs dSyndecan and
dDallylike opposingly regulate dLAR-mediated synaptic morpho-
genesis and active zone function12. While the interaction of
dLAR with presynaptic dSyndecan promotes bouton growth,
postsynaptic dDallylike competes with dSyndecan for dLAR
binding, leading to an inhibition of growth and active zone
stabilization12. Interactions of the RPTPs ectodomain with
HSPGs and CSPGs modulate axonal growth both during
development and post injury10,13,14,16. HSPGs cluster RPTPs, a
characteristic proposed to drive a localized imbalance of protein
tyrosine phosphorylation and hence promote growth14. Once the
axon has reached its ﬁnal target, RPTPs can establish direct
interactions with multiple postsynaptic proteins. In vertebrates,
these include the TrkC receptor protein tyrosine kinase, Netrin-G
ligand-3 (NGL-3), interleukin-1 receptor accessory protein and
Slit- and Trk-like receptors 1 and 2 (Slitrk1 and Slitrk2)17–20.
These trans-synaptic complexes mediate bi-directional excitatory
synapse formation, simultaneously triggering presynaptic
differentiation and an accumulation of synaptic vesicles, and
clustering of the postsynaptic density7,9.
There are two major neuronal RPTPs isoforms, sharing a
common intracellular catalytic region and an extracellular region
predicted to contain three immunoglobulin (Ig)-like domains
followed by either ﬁve or nine ﬁbronectin (FN) type III domains,
in the central and peripheral nervous systems, respectively21.
Further isoforms include a combination of four mini-exons
(meA-meD) that may modulate interactions with protein
partners (Fig. 1a)8,21. Previous mutagenesis and structural
studies have demonstrated that the proteoglycan-binding site
lies on Ig1 of RPTPs, and comprises an extended positively
charged surface of basic residues10,13,14. Binding of postsynaptic
TrkC, is reported to require the N-terminal three Ig domains of
RPTPs17; the NGL-3-binding site has been mapped to the FN1-2
domains18.
The properties that ﬁt the RPTPs ectodomain for its function
as an integrative hub for signalling in synaptogenesis are
unknown. Here we report a molecular level analysis of the
RPTPs ectodomain and of its direct interactions with the
postsynaptic binding partner TrkC. We reveal that the multi-
domain extracellular region of RPTPs is unexpectedly ﬂexible.
This characteristic confers sufﬁcient conformational freedom to
allow its binding to both pre- or postsynaptic ligands.
RPTPs:TrkC crystal structures provide an explanation for the
speciﬁcity of this interaction and also highlight an overlap of
TrkC and proteoglycan-binding sites on RPTPs. This observa-
tion suggests that there is competition between TrkC and heparan
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Figure 1 | RPTPr ectodomain ﬂexibility. (a) RPTPs domain organization. N, amino-terminus (extracellular); SP, secretion signal peptide;
TM, transmembrane; C, C terminus (intracellular); Ig, immunoglobulin-like; FN, ﬁbronectin type-III; GAG, glycosaminoglycan-binding site (ﬁlled
arrowhead). Alternative splicing inserts: FN domains 4–7 and mini-exons A–D (open arrowhead). (b) Ribbon and surface representations of the human
RPTPs Ig1-FN3 crystal structure. N-linked glycans in atom representation. (c) Ig3 movement in Ig1-FN3 relative to Ig1–3 (grey, PDB ID: 2YD9) structure.
Representative RPTPs Ig1-FN3 (d) and RPTPs sEcto (e) negative-stain electron microscopy class averages. Scale bar, 10 nm. Full sets of RPTPs
Ig1-FN3 and sEcto class averages are provided in Supplementary Figs 2 and 3.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6209
2 NATURE COMMUNICATIONS | 5:5209 | DOI: 10.1038/ncomms6209 |www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
sulphate for RPTPs binding, and we provide support for this
notion in biophysical and cellular assays. Overall, our study
provides novel insights into the mechanisms determining the
hierarchy and functional consequences of RPTPs–ligand
interactions.
Results
The RPTPr ectodomain exhibits extensive ﬂexibility. We ﬁrst
investigated the molecular characteristics of RPTPs that allow
presentation of the N-terminal Ig domains for both pre- and
postsynaptic ligand binding. We determined the 3.15Å crystal
structure of a six N-terminal domain human RPTPs construct
(termed Ig1-FN3, Fig. 1a), which contains all the binding sites for
synaptic ligands identiﬁed to date. This construct maintains the
V-shaped Ig1–2 arrangement previously reported14,22, followed by
an extended conformation of the sequential domains Ig3, FN1 and
FN2 (Fig. 1b; Table 1). Superposition of Ig1-FN3 with the crystal
structure of Ig1–3 (ref. 14) revealed a hinge point between domains
Ig2 and Ig3 (Fig. 1c). The four amino-acid meB exon would extend
this apparently ﬂexible linker further, by four residues
(Supplementary Fig. 1). While FN1 and FN2 domains align
approximately with the long axis of the molecule, the C-terminal
FN3 domain folds back, suggesting the FN2-3 linker may also be a
ﬂexion point. Since no substantial Ig3-FN1, FN1–FN2 or
FN2–FN3 inter-domain interfaces are apparent, we hypothesized
that when released from crystal packing constraints each of the
Ig2-FN3 region linkers may provide substantial ﬂexibility. To test
this, single-particle negative-stain electron microscopy (EM) class
averages of human RPTPs Ig1-FN3 were calculated. These
showed a broad range of conformations (Fig. 1d; Supplementary
Fig. 2). This ﬂexibility, reminiscent of hinge points in a-
neurexin23, is in marked contrast to the rigidity of homophilic
cell adhesion molecules of similar size and domain organization,
such as cadherins, RPTPm and SYG-1/SYG-2 (refs 24–26).
We extended our EM analysis to the full ectodomain of the
eight-domain isoform of human RPTPs (sEcto; Fig. 1a,e;
Supplementary Fig. 3). The 150 class averages generated reinforce
our conclusions from the six-domain structural analyses. The
RPTPs ectodomain exhibits a surprisingly large ﬂexibility, with
observed conformations ranging from almost fully extended, to
essentially bent double (Fig. 1e; Supplementary Fig. 3). To control
for the potential risk of artefacts associated with negative staining,
we also performed small-angle X-ray scattering (SAXS) measure-
ments, at a physiological pH (7.4), for both human RPTPs Ig1-
FN3 and sEcto. This analysis further supports the observation
that both proteins are ﬂexible and are likely to adopt multiple
conformations in solution (Supplementary Fig. 4). Taken
together, crystallographic, EM and SAXS analyses demonstrate
that the ectodomain of RPTPs is able to explore a large
conformational space.
Structural analysis of the RPTPr:TrkC trans-synaptic complex.
How do these conformational properties contribute to the
interaction of RPTPs with ligands? We sought to compare and
Table 1 | Data collection and reﬁnement statistics.
hRPTPr Ig1-FN3 cRPTPr Ig1-2 þ cTrkC LRRIg1cryst cRPTPr Ig1-3 þ cTrkC LRRIg12Q
Data collection
Space group P6122 P2 P1
Cell dimensions
a, b, c (Å) 198.8, 198.8, 132.4 68.3, 122.2, 98.6 84.4, 93.1, 99.4
a, b, g () 90.0, 90.0, 120.0 90.0, 109.8, 90.0 73.4, 89.5, 74.2
Resolution (Å) 99.40–3.15 (3.23–3.15)* 63.96–2.50 (2.56–2.50) 81.02–3.05 (3.13–3.05)
Rmerge 7.8 (99.1) 19.2 (142.4) 6.9 (34.7)
Rpim
w 3.2 (41.0) 5.7 (57.2) 5.6 (60.3)
CC1/2
z 99.8 (63.9) 99.5 (58.4) 99.8 (67.2)
I/sI 17.8 (2.1) 10.7 (1.6) 8.8 (1.5)
Completeness (%) 95.6 (96.1) 99.8 (99.3) 96.3 (96.6)
Redundancy 7.6 (7.5) 11.6 (7.1) 1.8 (1.8)
Reﬁnement
Resolution (Å) 99.40–3.15 (3.23–3.15) 63.96–2.50 (2.56–2.50) 81.02–3.05 (3.13–3.05)
No. reﬂections 25,619 (1,858) 52,652 (3,833) 51,063 (3,823)
Rwork/Rfree 23.4 (37.1)/26.5 (37.7) 20.9 (32.2)/24.7 (36.2) 22.6 (37.2)/24.0 (38.6)
No. of atoms
Protein 4,380 8,536 10,630
NAGs 2 5 1
SO4
2 ions — 2 —
Water — 118 —
B-factors
Protein 122.2 57.2 116.4
NAGs 153.0 83.0 176.3
SO4
2 ions — 90.9 —
Water — 45.0 —
R.m.s.d.
Bond lengths (Å) 0.005 0.008 0.006
Bond angles () 1.008 1.243 1.045
RPTP, Receptor protein tyrosine phosphatase; r.m.s.d., root mean squared deviation.
*Values in parentheses are for highest-resolution shell. Each structure is based on a single crystal.
wRpim (the precision-indicating merging R-value)¼ 1/(N 1) Rmerge, where N is the redundancy.
zCC1/2 is the mean intensity correlation coefﬁcient of half-data sets53.
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contrast complex formation between the RPTPs N-terminal
region and axonal HSPGs14 with the trans-synaptic interaction
between RPTPs and TrkC. The TrkC ectodomain comprises an
N-terminal leucine-rich repeat (LRR) domain, followed by two Ig
domains (Fig. 2a). Equilibrium surface plasmon resonance (SPR)
assays conﬁrmed previously reported data17 that the minimal
units required for full afﬁnity binding are RPTPs Ig1–3 and TrkC
LRRIg1 (Supplementary Fig. 5a,b; Supplementary Table 1).
RPTPs Ig1–2 does retain TrkC binding, although with an
approximately ﬁvefold-reduced afﬁnity compared with RPTPs
Ig1–3 (Kd¼ 2.4 mM versus 551 nM, Supplementary Fig. 5a). TrkC
LRRIg1 had also previously been shown to be the minimal unit
required for the synaptogenic activity of TrkC17. To facilitate
crystallization, a chicken TrkC construct (TrkC LRRIg1cryst)
was generated, which removed putative sites of N-linked
glycosylation and residues 63–77, a predicted disordered loop
(Supplementary Fig. 6). A 2.5 Å crystal structure of a chicken
RPTPs Ig1–2:TrkC LRRIg1cryst complex was determined,
revealing a 1:1 stoichiometry (Fig. 2b; Table 1; Supplementary
Fig. 5c), in agreement with results from multi-angle light
scattering (MALS) analysis (Supplementary Fig. 5d). The
structure is consistent with a trans RPTPs:TrkC complex
spanning the synaptic cleft (Fig. 2b). The V-shaped RPTPs
Ig1–2 module contacts an extended TrkC surface consisting of
the LRR convex face and Ig1 domain, with a buried surface area
of 1,093Å2 per molecule (Fig. 2b).
Three major contact sites constitute the protein–protein
interface in the complex crystal structure: site 1, RPTPs Ig1:TrkC
Ig1 (Fig. 2c; Supplementary Fig. 7); site 2, RPTPs Ig1:TrkC
LRRIg1 inter-domain region (Fig. 2d; Supplementary Fig. 7)
and site 3, RPTPs Ig2:TrkC LRR (Fig. 2e; Supplementary Fig. 7).
Electrostatic interactions involving RPTPs residues R96 and
R99 and TrkC residues D240 and D242 dominate interactions at
site 1 (Fig. 2c). Intriguingly, R96 and R99 form part of the
extended positively charged surface on RPTPs Ig1 (ref. 14) and
are absolutely required for RPTPs interactions with HSPGs10,14,
suggesting that TrkC and proteoglycans may compete for
binding to RPTPs. At site 2, Q75 in RPTPs, interacts with
TrkC residues E287 and Q148, while the side chains of RPTPs
E78 and TrkC R121 form a salt bridge (Fig. 2d). Site 3 centres on
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Figure 2 | Trans-synaptic RPTPr:TrkC complex crystal structure. (a) TrkCTK- (non-catalytic isoform) domain organization. LRR, leucine-rich repeat
region (N, N-terminal cysteine-rich region; 1–3, leucine-rich repeats; C, C-terminal cysteine-rich region). Putative N-linked glycosylation sites, lollipops;
ﬁlled lollipops remain in LRRIg1cryst construct. (b) Space-ﬁlled and tube representations of chicken RPTPs Ig1–2:TrkC LRRIg1cryst crystal structure.
N-linked glycans in atom representation. Disordered RPTPs Lys-loop, blue dotted line; TrkC LRRIg1cryst amino-acid residue 62–78 junction, asterisk.
(c–e) Detailed view of bonding interactions at RPTPs:TrkC interface for binding sites 1–3. Corresponding electron density is illustrated in Supplementary
Fig. 7. Potential electrostatic and hydrogen bonds, black dashed lines; oxygen atoms, red; nitrogen atoms, bluewhite.
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a K203–E100 salt bridge between RPTPs and TrkC residues,
respectively (Fig. 2e).
These three interaction sites are consistent with RPTPs
binding TrkC, but not TrkA or TrkB17; of the six
predominantly charged (D240, D242, E287, Q148, R121 and
E100) TrkC residues observed to have side-chain-mediated
RPTPs interactions, only E287 is conserved across the other
Trk family members (Supplementary Fig. 6). Although the key
RPTPs residues discussed above are conserved in human RPTPd
and LAR (Supplementary Fig. 1), the speciﬁcity of TrkC binding
for RPTPs can be rationalized through closer inspection of type
IIa RPTP sequence alignments and the chicken RPTPs Ig1–
2:TrkC LRRIg1cryst crystal structure (Fig. 3a). At site 1, we
hypothesized that substitution of P98 (in RPTPs) to H98 in
RPTP LAR, would result in a movement of the carbonyl group of
T97 to ease the cis-conformation of residue 98 to trans (see PDB
ID: 2YD5), disrupting interaction with the TrkC H254 carbonyl
group. At site 2, we anticipated that substitution of S74 (in
RPTPs) to N74 in RPTPd would result in the loss of this
residue’s interaction with TrkC D240. To validate these
predictions, RPTPs Ig1–3 P97VþT98H (LAR-like Ig1–3) and
N73Sþ S74N (RPTPd-like Ig1–3) proteins were generated, which
indeed displayed LAR- and RPTPd-like binding to TrkC in SPR
analyses (Fig. 3b,c; Supplementary Fig. 8a,b; Supplementary
Table 1).
Validation of the RPTPr:TrkC binding mode. To conﬁrm the
contribution of the RPTPs:TrkC interaction sites, we introduced
point mutations into the interfaces on either protein (Fig. 4a) and
measured the resulting dissociation constants (Kd) using SPR. As
predicted, mutations in either TrkC (D240AþD242A) or
RPTPs (R96AþR99A, affecting the glycosaminoglycan (GAG)-
binding arginine residues), completely abolished both human and
chicken RPTPs binding to mouse and chicken TrkC, respectively
(Fig. 4b,c; Supplementary Fig. 8c–f; Supplementary Table 1). The
RPTPs Y223S mutation was designed to disrupt binding at site 3
by introducing an N-linked glycosylation site at N221, and
RPTPs:TrkC binding was indeed ablated (Fig. 4c; Supplementary
Fig. 8e,f; Supplementary Table 1). In agreement with the struc-
tural and biophysical data, TrkC transmembrane (TrkC TM)
D240AþD242A expressing COS-7 cells, unlike wild-type TrkC
TM expressing positive controls, were unable to induce pre-
synaptic differentiation in co-cultured rat hippocampal neurons
despite comparable levels of cell surface expression (Fig. 4d;
Supplementary Fig. 9).
We had noted that the interaction afﬁnity between engineered
proteins used for RPTPs:TrkC complex crystallization (chicken
RPTPs Ig1–3 and TrkC LRRIg1cryst) was some 20-fold lower
following the TrkC 63–77 loop deletion (Kd 4.8 mM versus
216 nM; Fig. 5a; Supplementary Fig. 8g; Supplementary Table 1).
We therefore explored the possible contribution of the 63–77
loop to the RPTPs:TrkC interaction by engineering a construct
termed TrkC LRRIg12Q, comprising the full sequence but still
removing two predicted N-linked glycosylation sites by introdu-
cing N68Q and N72Q mutations (Supplementary Fig. 6). This
construct did indeed bind RPTPs with enhanced afﬁnity (Fig. 5a;
Supplementary Fig. 8g,h; Supplementary Table 1), while TrkC
TM2Q induced comparable levels of presynaptic differentiation in
co-cultured rat hippocampal neurons to wild-type TrkC TM
(Fig. 4d). We determined the 3.05 Å crystal structure of this
chicken RPTPs Ig1–3:TrkC LRRIg12Q complex in an attempt to
visualize this additional, fourth, binding site (Table 1). Crystals
grew in a new space group, P1, with three RPTPs:TrkC
complexes in the asymmetric unit (a.s.u.). These align very
closely with the two complexes/a.s.u. observed in the previous P2
structure (Fig. 5b; root mean squared deviation between 446
equivalent Ca residues of the P2 complex1 relative to P2
complex2 and P1 complexes1-3 was calculated to be 0.82Å,
0.83 Å, 0.80Å and 0.70Å, respectively), providing additional
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Figure 3 | TrkC binding preferences for type IIa RPTP family members. (a) Type IIa RPTP sequence alignments and detailed views of the RPTPs:TrkC
crystal structure at binding site 1 (left) and binding site 2 (right). Blue boxes indicate RPTPs residues required for proteoglycan binding, and red
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support for the relevance of the observed RPTPs:TrkC interac-
tion mode. The site 4 interface is not well resolved in this 3.05-Å
resolution structure, although we do observe an additional TrkC
helix (formed by residues 69–80), which interacts with RPTPs
Ig2 predominantly via potential packing of the I73 side chain
against a hydrophobic region consisting of RPTPs residues V144,
Y223 and TrkC L56, T74 and L101 (Fig. 5c,d). The RPTPs
Ig2–Ig3 linker (V226-A230) and the Ig3 domain also lack well-
ordered electron density in this structure. However, a R227Aþ
R228A double mutation reduced RPTPs:TrkC binding (Fig. 4c;
Supplementary Fig. 8e,f; Supplementary Table 1), as did insertion
of the meB mini-exon between R225 and V226 in SPR-binding
assays, supporting the involvement of the RPTPs Ig2–Ig3
linker in the auxilary binding site 4 (Supplementary Fig. 8i;
Supplementary Table 1).
HSPGs compete with TrkC for RPTPr binding. The overlap of
the TrkC- and GAG-binding sites on RPTPs, prompted us to
investigate the notion that proteoglycan competition with TrkC
has the potential to modulate RPTPs function in synaptogenesis.
Initially, we tested whether soluble HS or the HS-mimetic
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heparin-dp10 could inhibit the interactions between TrkC and
either wild-type RPTPs or a quadruple K67AþK68Aþ
K70AþK71A mutant (RPTPs Ig1–3 DK), which precludes GAG
binding14 while retaining wild-type TrkC binding (Fig. 6;
Supplementary Fig. 10a,b; Supplementary Table 1). Increasing
concentrations of HS or heparin-dp10 were able to inhibit the
binding of RPTPs Ig1–3 WT, but not RPTPs Ig1–3 DK to
immobilized TrkC LRRIg1 (Fig. 6a; Supplementary Fig. 10a,b;
Supplementary Table 1). To investigate the TrkC versus GAG
competition in a cellular setting, we added heparin-dp10 to co-
cultures of TrkC TM expressing COS-7 cells and rat hippocampal
neurons. Induced presynaptic differentiation in the neurons
decreased by twofold compared with mock-treated co-cultures
upon heparin-dp10 addition (Fig. 6b,c). Furthermore, treatment
of co-cultures with a mixture of heparinases I, II and III, to digest
heparan sulphate GAGs, signiﬁcantly enhanced presynaptic
induction by TrkC TM (Fig. 6b,c), suggesting that native
HSPGs may limit synapse development through RPTPs:TrkC,
by direct competition for binding (Fig. 6d). In contrast to
TrkC, the interaction of RPTPs with another trans-synaptic
protein ligand, NGL-3, reported to bind at the FN1-2 domains,
appears insensitive to proteoglycans. Neither heparin-dp10 nor
heparinase treatment affected NGL-3-induced synaptogenesis
in the co-culture system (Fig. 6b,c), and RPTPs:NGL-3
binding in SPR assays showed no major reduction upon HS
addition (Supplementary Fig. 10c,d; Supplementary Table 1).
Discussion
While all three vertebrate type IIa RPTP family members bind
NGL-3 (refs 18,27) and interleukin-1 receptor accessory
protein19, and both RPTPs and RPTPd bind to Slitrk1 and
Slitrk2 (refs 20,28), the IL-1 receptor accessory protein-like 1
(IL1RAPL1) interacts predominantly with RPTPd29,30 and the
receptor protein tyrosine kinase TrkC interacts with RPTPs17.
We therefore used this latter protein–protein interaction as our
exemplar for trans-synaptic RPTPs action. RPTPs and TrkC
exhibit broad and overlapping expression patterns in the adult
nervous system18,21,31–33. Multiple ligand interactions and
signalling pathways are disrupted in RPTPs- and TrkC-
deﬁcient mice though, making assessment of any overlap in
phenotypes difﬁcult34–37. A direct comparison of the effect of
either TrkC knockdown17 or RPTPs knockout38,39 upon synapse
structure and number in vivo, is similarly complicated by the
parallel role of RPTPs in regulating axon sprouting. The detailed
explanation of RPTPs:TrkC speciﬁcity that we offer in this study
provides the information to enable the design of new experiments
to dissect the precise contribution of this interaction to
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synaptogenesis in vivo. The locations of RPTPs and TrkC are
primarily reported as pre- and postsynaptic, respectively8,9, and
we depict them as such in our model (Fig. 7). However, there is
evidence that this may be too simplistic, for example, the type IIa
RPTPs have also been reported in postsynaptic compartments7.
The extent of ﬂexibility we observe for the RPTPs ectodomain,
suggests that the RPTPs:TrkC binding mode revealed by our
crystal structures may also mediate cis interactions in the event of
co-localization of the two receptors at the same cell surface.
Our data reveal several key properties that ﬁt RPTPs for its
dual role as a synaptic signalling hub and a promoter of neuronal
growth. During axonal extension, RPTPs interacts with proteo-
glycan molecules through its N-terminal Ig1 domain, the
clustering properties of HSPGs promoting growth cone moti-
lity14. The RPTPs ectodomain architecture described here
indicates that a range of conformations can be explored,
permissive of cis interactions at the axonal surface and trans
interactions to the general extracellular milieu including the
basement membrane (Fig. 7a). Indeed, the length of the RPTPs
ectodomain may be important to extend the HSPG-binding site
beyond a saturating layer of cis interactions at the same cell
surface, similar to the sialic acid-binding Siglec family of cell
surface receptors where a lengthy ectodomain is required to
escape the inhibitory glycocalyx40. At the transition from
extension to synaptogenesis, the postsynaptic neuronal surface
presents an array of additional RPTPs ligands (Fig. 7b)8,9.
Synapse formation and development requires the selection of an
appropriate subset of binding partners. This involves a simple
kinetic competition for binding, governed by inter-molecular
afﬁnity and interaction site accessibility. Our analyses suggest that
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this selection may be choreographed by the interplay of binding
site location and conformational ﬂexibility in the RPTPs
ectodomain. Structural comparison of the RPTPs:TrkC
complex with our previously reported interaction mode for type
IIa RPTP:GAGs14 shows partially overlapping binding sites
(Fig. 6d). Thus, during synapse formation, and the shift from
axonal growth to synaptic stability, postsynaptic TrkC must out-
compete proteoglycans for RPTPs binding, simultaneously
providing an adhesive trans interaction and extinguishing the
RPTPs-clustering activity of HSPGs (Fig. 7b). Neuronal and glia-
released proteoglycans continue to play important roles at
synapses41,42, however, their contribution may involve other
trans-synaptic interactions, for instance other type IIa RPTP
family members or LRRTM4 (refs 43,44).
Alternative splicing has been shown previously to control the
speciﬁcity of trans-synaptic interactions of the type IIa
RPTPs8,17,20,28,29. The impact of alternative splicing at RPTPs
mini-exon site meB on TrkC binding afﬁnity provides a potential
rheostat by which to ﬁne-tune the balance between competing
RPTPs ligands, an analogous feature to neurexin splice site 4
control of ligand interactions at the synaptic cleft8,45,46. The meA
mini-exon is absent from all the RPTPs constructs used in this
study, but its insertion into the Ig2 bD–bE loop (b11–b12 loop in
Supplementary Fig. 1) is unlikely to affect binding of RPTPs to
TrkC, as it would lie on the opposite face to the TrkC-binding
interface. Both meA and meB sites are remote from the GAG-
binding surface on RPTPs Ig1 (ref. 14) and therefore neither
insertion is expected to modulate binding of RPTPs to
proteoglycans.
Trans-synaptic binding to TrkC will limit the conformational
freedom of the RPTPs ectodomain. This reduces the entropic
penalty for binding at other sites on RPTPs, an effect which can
potentiate the formation of cell surface assemblies involving
multiple receptor interactions47. For RPTPs function at the
synapse this may facilitate cooperative binding of TrkC and NGL-
3, as these two binding sites are separate18 (Fig. 7b). TrkC can
also bind the NT-3 neurotrophin, a modulator of synaptic
transmission, at the second Ig domain48 (Fig. 7b), which adds a
further, distinctive stoichiometry to this network of trans-
synaptic interactions, by speciﬁcally triggering dimerization of
TrkC and hence RPTPs. Other soluble modulators, such as the
astrocyte-derived HSPGs glypican-4 and glypican-6, may provide
an alternative strategy to regulate this system41. The
stoichiometry and architecture of higher-order trans-synaptic
complexes, and their impact on RPTPs enzymatic activity,
remain important questions to address in the future. Formally, we
cannot yet exclude a scenario where the simple kinetics of
competition between ligands may be sufﬁcient to explain the
phenotypes observed in our cellular assays. However, given the
geometrical constraints within which the RPTPs ectodomain has
to operate at points of cellular contact, with ligands present in
both cis and trans orientations, it is very likely that the RPTPs
ectodomain ﬂexibility is required in a physiological context.
A series of proteolytic processing events have been reported for
the type IIa RPTPs at the cell surface, involving initial shedding of
the ectodomain, prior to release of the intracellular catalytic
domains49. In our crystallization trials, we have potentially
identiﬁed a further receptor-cleavage site at the consensus furin-
like protease motif RVRR on the Ig2–Ig3 linker, which would be
disrupted in RPTPs isoforms containing mini-exon meB.
Cleavage of either RPTPs Ig1–2 or ectodomain fragments
would ﬁrst decouple the receptor phosphatase activity from
regulation via both proteoglycan and TrkC binding, and second
the released soluble RPTPs fragments would be able to compete
with the remaining intact receptors for binding to these same
ligands. Knockout of the Drosophila type IIa RPTP dLAR, can be
rescued by reintroduction of a catalytically inactive receptor, but
not by a dLAR construct lacking the second inactive phosphatase
domain (D2)50. It remains to be determined whether RPTPs
ectodomain–ligand interactions may regulate the availability of
RPTPs D2 for binding downstream intracellular partners8,9, but
any such mode of regulation would also be ablated by
extracellular RPTPs cleavage events.
In conclusion, our results suggest how the RPTPs nexus
utilizes a series of ﬁltering mechanisms to discriminate between
binding options, and ultimately integrate the signalling inputs
essential for the transition from neuronal growth to synapse
organization. Rigidity has been demonstrated to be central for the
comparatively simpler adhesion molecule function24–26. In
contrast, the properties of RPTPs described here, prompt the
notion of how ectodomain ﬂexibility can allow a cell surface
receptor to integrate a broad spectrum of ligand interactions into
distinct functional outcomes.
Methods
Construct design and cloning. Human RPTPs Ig1–3, Ig1-FN3 and sEcto pHLsec
constructs were reported previously14. The chick RPTPs Ig1–3 construct (amino
acids 29–316, NCBI Ref. Seq. NM_205407.1) was cloned into pHLsec and pHL-
Avitag3 vectors51. A series of chick RPTPs Ig1–3 mutant constructs were
generated by PCR: K67AþK68AþK70AþK71A (chick RPTPs Ig1–3 DK),
N73Sþ S74N, R96AþR99A, P97VþT98H, K203A, Y223S and R227AþR228A
and subsequently cloned into the pHL-Avitag3 vector. Human RPTPs Ig1–3
K68AþK69AþK71AþK72A (human RPTPs Ig1–3 DK), R97AþR100A,
Y224S and R228AþR229A C-terminal Avitag constructs were similarly
constructed. Human RPTPd sEcto (amino acids 21–833, NCBI Ref. Seq.
BC106713.1), and human RPTP LAR Ecto (amino acids 30–1,260, NCBI Ref. Seq.
NM_002840.3) were also cloned into the pHL-Avitag3 vector.
A synthetic clone for chick TrkC was commercially synthesized (Source
Bioscience); to include amino-acid residues 32–302 (NCBI Ref. Seq.
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Figure 7 | Model illustrating ﬂexible RPTPr ectodomain sampling of
extracellular ligands. (a) At the growth cone, RPTPs interacts with cell
surface and basal membrane proteoglycans to mediate axonal extension.
(b) Upon contact with target cells, to shift to the role of synaptic organizer,
RPTPs adopts elongated conformations to protrude from the presynaptic
proteoglycan haze and bind postsynaptic ligands such as TrkC and NGL-3.
Subsequent independent or coordinated interactions with additional
synaptic ligands are shown. Red boxes (left hand panels) indicate growth
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NM_205169.1), but lack residues 63–77 and include the following point mutations:
N163Q, N232Q, N259Q, N267Q and N294Q, to reduce the number of N-linked
glycosylation sites. This construct (chick TrkC LRRIg1cryst) was cloned into the
pHL-Avitag3 vector. A series of further chick TrkC LRRIg1 mutant constructs were
generated by PCR: D240AþD242A, re-addition of residues 63–77 (chick TrkC
LRRIg12N) and re-addition of residues 63–77 with N68QþN72Q point mutations
(chick TrkC LRRIg12Q).
A series of mouse TrkC constructs (NCBI Ref. Seq. BC139764.1) were cloned
into both pHLsec and pHL-Avitag3 vectors: LRR (amino acids 32–208), LRRIg1
(amino acids 32–302) and LRRIg2 (amino acids 32–398). A mouse TrkC TM
(amino acids 32–463) construct was cloned into the pHLsec-monoVenus vector.
The following mouse TrkC mutant constructs were generated by PCR:
D240AþD242A (LRRIg1 and TM constructs), N68QþN72Q (LRRIg12Q and
TM2Q) and removal of residues 63–77 (LRRIg1cryst). Mouse NGL-3 (NCBI Ref.
Seq. BC060263.1) ectodomain (NGL-3 Ecto; amino acids 1–574) and full-length
(NGL-3 FL; amino acids 1–709) constructs were cloned into pHL-Avitag3 and
pHLsec-monoCerulean vectors, respectively.
Protein puriﬁcation and crystallization. For crystallization purposes, constructs
were expressed in either HEK-293S GnTI cells (chicken RPTPs Ig1–3, TrkC
LRRIg1cryst and TrkC LRRIg12Q) or HEK293-T cells treated with kifunensine
(human RPTPs Ig1-FN3) following transient transfection using poly-
ethylenimine51. The proteins were puriﬁed from 0.2-mm-ﬁltered cell culture media
by immobilized nickel afﬁnity chromatography (Chelating Sepharose Fast Flow,
GE Healthcare) followed by size-exclusion chromatography in 10mM HEPES,
150mM NaCl, pH 7.5.
Crystallization trials, using 100 nl protein solution plus 100 nl reservoir solution
in sitting-drop vapour diffusion format were set up in 96-well Greiner plates using
a Cartesian Technologies robot, and plates were subsequently maintained at
20.5 C in a TAP Homebase storage vault. The crystallization conditions yielding
diffraction quality crystals were: 10% polyethylene glycol (PEG) 20 k, 20% PEG
MME 550, 0.1M bicine/Tris pH 8.5, 0.03M sodium nitrate, 0.03M disodium
hydrogen phosphate, 0.03M ammonium sulphate (chicken RPTPs Ig1–2:TrkC
LRRIg1cryst complex 2.5 Å data set), 10% w/v PEG MME 5 k, 0.1M HEPES pH 7.0,
5% w/v Tacsimate (chicken RPTPs Ig1–3:TrkC LRRIg12Q complex 3.05 Å data set)
and 10% PEG 400, 0.01M magnesium chloride, 0.1M potassium chloride, 0.05M
MES pH 6.0 (human RPTPs Ig1-FN3).
Data collection and processing. Crystals were cryoprotected using a 25–30%
solution of ethylene glycol (chicken RPTPs Ig1–2:TrkC LRRIg1cryst and RPTPs
Ig1–3:TrkC LRRIg12Q complexes) or 25% propylene glycol (human RPTPs Ig1-
FN3) and then ﬂash-cooled at 100 K. X-ray diffraction data were collected at the
I03 (chicken RPTPs Ig1–3:TrkC LRRIg12Q; wavelength 0.9763Å) and I04 (chicken
RPTPs Ig1–2:TrkC LRRIg1cryst; wavelength 0.9200Å) beamlines Diamond Light
Source, Oxfordshire, UK and the ID29 (human RPTPs Ig1-FN3; wavelength
0.9788Å) beamline at the European Synchotron Radiation Facility, Grenoble,
France. The diffraction images were indexed, integrated, scaled and merged using
the xia2 data-processing suite52. We used Rpim, I/sI and CC1/2 (ref. 53) statistics in
the highest-resolution shell (with criteria Rpimo100%, I/sI41.5 and CC1/2450%)
to determine our high-resolution cutoffs (see Table 1).
Molecular replacement was used to phase all three crystal structures, using
human and chicken RPTPs Ig1–2 (PDB ID: 2YD3 and 2YD4), human RPTPs Ig3
(from PDB ID: 2YD9), a Ca model for human RPTP LAR FN4 (PDB ID: 2DJU)
and models of the chicken TrkC LRR and ﬁrst Ig domain (Ig1) generated using the
SWISS-MODEL web interface54, as search models in Phaser55. Manual model
adjustment was performed in Coot56 and the Refmac57, Phenix58 and Buster
(Global Phasing Ltd)59 suites used for reﬁnement (applying translation libration
screw-motion restraints for all structures and local non-crystallographic symmetry
restraints for RPTPs:TrkC complex structures). Stereochemical properties of all
models were accessed using MolProbity60. Ramachandran statistics: human
RPTPs Ig1-FN3, 94.0% most favoured, 6.0% additionally allowed and no
disallowed rotamers; chicken RPTPs Ig1–2:TrkC LRRIg1cryst, 98% most favoured,
2% additionally allowed and no disallowed rotamers; chicken RPTPs Ig1–3:TrkC
LRRIg12Q, 96.6% most favoured, 3.2% additionally allowed and 0.2% disallowed
rotamers. Full data collection and reﬁnement statistics are given in Table 1.
The 3.15-Å human RPTPs Ig1-FN3 crystal structure contains one molecule per
asymmetric unit; amino residues 35–601, an additional C-terminal G residue
derived from the expression vector and two GlcNAc residues at N-linked
glycosylation sites N250 and N295.
The 2.5 Å chicken RPTPs Ig1–2:TrkC LRRIg1cryst crystal structure contains
amino-acid residues 32–302 for two molecules, A and B, of TrkC LRRIg1 (lacking
residues 63–77 absent in the TrkC LRRIg1cryst expression construct and residues
258–261 on a disordered Ig1 loop, but with ETG (A) and G (B) additional N-term
residues and GT (A) and G (B) additional C-term residues derived from the
expression plasmid) and residues 29–227, 29–226 and 29–228 for three molecules,
C, D and E, of RPTPs Ig1–2 (with the exception of a disordered loop for each
molecule, 68–71(C), 68–70(D) and 68–73(E)). Five TrkC N-linked glycosylation
sites were modelled; initial N-acetylglucosamine (GlcNAc) residues, covalently
bonded to N79 (A and B), N203 (A) and N272 (A and B) were included in the
structure. Inspection of the crystal packing clearly demonstrates that the Ig3
domains of the RPTPs Ig1–3 crystallization protein are not present in these
crystals. Proteolytic cleavage is the most likely reason for their absence, as we have
commonly seen cleavage of wild-type RPTPs Ig1–3 at the Ig2–Ig3 linker during
crystallization trials. The previously reported human RPTPs Ig1–2 crystal
structure was obtained via proteolysis of Ig1–3 during crystallization (PDB ID
2YD3). To produce crystals of intact human RPTPs Ig1–3, R227QþR228N
(residue numbering relative to chicken RPTPs) point mutations were previously
introduced to disrupt a potential furin protease motif14. However, RPTPs R227
and R228 are required for full RPTPs:TrkC binding (Fig. 4c; Supplementary
Fig. 8e,f; Supplementary Table 1) and therefore the RPTPs Ig1–3 R227QþR228N
protein was not used in crystallization trials in this study.
The 3.05 Å chicken RPTPs Ig1–3:TrkC LRRIg12Q crystal structure contains
amino-acid residues 32–302 for three molecules, A, B and C, of TrkC LRRIg1
(lacking residues 59–68 (A), 59–68 (B) and 57–73 (C), but with TG (A), G (B) and
G (C) additional N-term residues derived from the expression plasmid) and
residues 29–226, 29–227 and 29–225 for three molecules, D, E and F, of RPTPs
Ig1–3 (with the exception of residues 67–71 in the disordered ‘Lys-loop’ for each
molecule, for which density was visible, but a single conformation could not be
built). Electron density was visible to indicate the presence of N-linked
glycosylation adjacent to N79 in TrkC molecules A–C, but only in molecule A
could an initial GlcNAc residue be successfully reﬁned. There was also evidence
that N218 (electron density corresponding to molecule B) and N272 (electron
density corresponding to molecule A) are also N-linked glycosylation sites. Sparse
electron density is visible for RPTPs Ig3, suggesting disorder/multiple
conformations of this domain.
The assignment of secondary-structure elements was performed using ksdssp61.
The superposition of atomic models to compare the domain architecture between
different structures was performed using SHP62, based on Ca positions.
Crystallographic ﬁgures were created using PyMOL (Schro¨dinger, LLC) and
APBS63 was used to calculate the electrostatic potential of solvent-accessible
surfaces.
Surface Plasmon Resonance. All SPR experiments were performed on BIAcore
T100 or T200 instruments. Ligand constructs were expressed in HEK293-T cells
with no kifunensine treatment and puriﬁed via Ni-afﬁnity chromatography. All
contained a C-terminal BirA recognition site (Avitag) and were biotinylated
enzymatically prior to immobilization to the surface of CM5 sensor chips (BIA-
core) pre-coated with streptavidin (Sigma) using the BIAcore amine-coupling kit.
Analyte constructs were expressed in either GnTI HEK293-S or HEK293-T cells
and puriﬁed as for crystallization purposes, described above.
Unless otherwise stated, experiments were all performed in 10mM HEPES pH
7.5, 150mM NaCl, 0.01% Tween 20, at a temperature of 25 C and a ﬂowrate of
20 ml min 1. Typically, each analyte sample was injected across the chip surfaces
for 120 s and then a 300 s dissociation time was included to allow the signal to
return to baseline. For equilibrium SPR experiments, serial two- or threefold
dilutions of protein analyte were sequentially injected and all injection series were
repeated in duplicate. No regeneration of the chip surfaces was required between
analyte injections, except when measuring the interaction between chicken TrkC
LRRIg12Q and chicken RPTPs Ig1–3, when a 30 s injection of 1M MgCl2 was
sufﬁcient for the signal to return to baseline.
Scrubber2 (BioLogic Software) and Prism (GraphPad Software) were used for
data analysis assuming the Langmuir model and a 1:1 ligand to analyte ratio. The
signal for experimental ﬂow cells was corrected by initial subtraction of a blank
(only buffer injected as analyte across the ﬂow cell of interest), followed by the
subtraction of the reference signal from a mock-coupled ﬂow cell (streptavidin, but
no ligand bound). To estimate half-maximal inhibitory concentration values for
heparan sulphate or heparin-dp10 inhibition of RPTPs:TrkC binding, nonlinear
regression in Prism (GraphPad Software) was used to ﬁt a variable-slope dose–
response curve to the experimental data, ﬁxing top and bottom values according to
control measurements (top; response units when no inhibitor present and bottom;
response units when no protein analyte or inhibitor present), while the Hill Slope
coefﬁcient and half-maximal inhibitory concentration variables were left
unrestrained.
Multi-Angle Light Scattering. MALS experiments were carried out on a Wyatt
MALS/AFFFF System (Wyatt Technologies). Human RPTPs Ig1-FN3 and mouse
TrkC LRRIg1 proteins were expressed in GnTI HEK-293S cells and puriﬁed as
described above. Size-exclusion chromatography was performed in 10mM Tris,
50mM NaCl, pH 7.5 on a Superdex200 HR10/30 column (GE Healthcare),
attached to an Agilent chromatography system. An Optilab rEX Refractive Index
detector and a Dawn Helios II Multi-Angle Light Scattering detector recorded the
refractive index and light scattering of the samples upon elution from the size-
exclusion column. The Wyatt software ASTRA was used to analyse all the data
collected.
Negative-stain EM. Human RPTPs Ig1-FN3 and sEcto proteins were negatively
stained with 0.7% uranyl formate64. Images were recorded using an FEI electron
microscope equipped with a LaB6 ﬁlament operated at an acceleration voltage of
200 keV at a magniﬁcation of  55,000 and a defocus value of approximately
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 1.5 mm. All images were recorded using SO-163 ﬁlm and developed with a
Kodak D-19 developer at full strength for 12min at 20 C. The electron
micrographs were digitized with a CoolScan 9000 (Nikon) using a step size
6.35 mm, and the pixels were binned by a factor of 3. As a result, the specimen level
pixel size was at 3.8 Å. To generate projection averages, particles were interactively
selected using the WEB display program in SPIDER65 and windowed into 90 90-
pixel (human RPTPs Ig1-FN3) and 100 100-pixel (human RPTPs sEcto)
images. Class averages were calculated using these windowed images over 10 cycles
of K-means classiﬁcation and multi-reference alignment specifying 150 classes64.
SAXS. RPTPs Ig1-FN3 and sEcto proteins were deglycosylated by Endo-F1 and
puriﬁed by SEC immediately prior to data collection. Solution scattering data were
collected at beamline BM29 of the European Synchotron Radiation Facility66 at
293K within a momentum transfer range of 0.01Å 1oqo0.45 Å 1, where
q¼ 4psin(y)/l and 2y is the scattering angle. X-ray wavelength was 0.995Å and
data were collected on a Pilatus 1M detector. RPTPs Ig1-FN3 was measured at
1.33 and 5.33 g l 1 and RPTPs sEcto at 1.00 and 4.00 g l 1. Data reduction and
calculation of invariants was carried out using standard protocols implemented in
the ATSAS software suite67. A merged data set was obtained by merging the low-
angle part of the low-concentration data set with the high-angle part of the high-
concentration data set.
A pool of 10,000 independent model conformers was constructed using the
program RANCH67 for both RPTPs Ig1-FN3 and sEcto by treating individual
domains as beads-on-a-string. For RPTPs sEcto, a homology model for domains 8
and 9 was created using SWISS-MODEL54. Both pools contained conformer shapes
ranging from collapsed or U-shaped to fully extended, as evidenced by their
Gaussian RG and DMAX distributions. Ensemble selection using the experimental
SAXS data as constraint with the programs GAJOE67 or MES68 indicated
predominantly extended conformers, consistent with the experimentally
determined RG and DMAX. The MES-selected models were used as starting
structures for further modelling. Missing loops and N- and C termini were added
in extended conformations using the program Modeller. All-atom simulations of
RPTPs Ig1-FN3 and sEcto was performed using the program AllosMod. For each
starting structure, 30 independent pools of 100 models were generated. For the
combined pool, calculation and ﬁtting of scattering patterns was performed using
the program FoXS, and automated selection of the minimal set of models satisfying
the scattering data was performed using the program MES; this whole procedure
was automated using the AllosMod-FoXS web server68.
Neuron-COS cell co-culture assays. Dissociated primary hippocampal neuron
cultures were prepared from embryonic day 18 rat embryos69. For co-culture
assays, COS-7 cells were transfected and 24 h later were seeded onto neurons at 14
days in vitro70. As indicated, co-culture coverslips were incubated with 0.2Uml 1
heparinase I, II and III or with 30 mgml 1 (B10mM) heparin-dp10 (Iduron Ltd,
UK) in glial conditioned medium. Co-cultures were ﬁxed with 4% formaldehyde
and 4% sucrose in phosphate-buffered saline (PBS) (pH 7.4) followed by
permeabilization with 0.2% Triton X-100. For cell surface staining of TrkC, COS-7
cells were ﬁxed without permeabilization. Fixed cultures were blocked in 3% bovine
serum albumin and 5% normal goat serum in PBS for 30min at 37 C, and primary
antibodies (overnight incubation at 4 C) then secondary antibodies (1 h at 37 C)
were applied in 3% bovine serum albumin and 5% normal goat serum in PBS.
Coverslips were mounted in elvanol (Tris-HCl, glycerol and polyvinyl alcohol, with
2% 1,4-diazabicyclo[2,2,2]octane). The primary antibodies were: anti-TrkC (1:500;
C44H5; Cell Signaling), anti-synapsin I (rabbit, 1:2,000; Millipore; AB1543P) for
presynaptic terminals, anti-MAP2 (chicken polyclonal IgY; 1:2,000; Abcam;
ab5392) for dendrites and anti-dephospho-tau (mouse mIgG2a 1:2,000, clone
PC1C6; Millipore; MAB3420) for axons.
All image acquisitions, analyses and quantiﬁcations were performed by
investigators blind to the experimental condition. For co-cultures, ﬁelds for
imaging were chosen only by the Cyan Fluorescent Protein (CFP) or mVenus and
phase-contrast channels, for the presence of CFP or mVenus-positive COS-7 cells
in a neurite-rich region. The synapsin channel was thresholded and the total
intensity of puncta within all regions positive for both CFP or mVenus and
dephospho-tau but negative for MAP2 was measured. Analysis was performed
using Fiji (ImageJ2), and GraphPad Prism 5. All data are reported as mean±s.e.m.
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